Donald Trump Restores Public School Program Axed by Obama Administration
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
President Donald Trump on Thursday will move to reinstate the Presidential Fitness Test, a decades-old program designed to encourage healthy, active lifestyles among American schoolchildren.
First launched in 1966, the test once required students to run and complete exercises such as situps, pullups or pushups, along with a sit-and-reach flexibility assessment. It was overhauled in 2012 under the Obama administration to emphasize personal health goals rather than athletic performance.
Trump "wants to ensure America's future generations are strong, healthy, and successful," White House press secretary Karoline Leavitt said in a statement, adding that the goal is to foster "a culture of strength and excellence for years to come." In a White House ceremony Thursday afternoon, Trump is expected to sign an order reestablishing both the President's Council on Sports, Fitness and Nutrition and the fitness test itself. Health Secretary Robert F. Kennedy Jr. will oversee the program, which will also introduce a new Presidential Fitness Award.
This is a breaking news story. Updates to follow.
This article includes reporting by the Associated Press.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
2 hours ago
- Washington Post
States sue Trump administration over access to care for transgender youths
A coalition of more than a dozen states sued the Trump administration on Friday over health care for transgender young people, claiming the White House has 'relentlessly, cruelly, and unlawfully targeted transgender individuals' since President Donald Trump took office. The lawsuit, filed in federal court in Massachusetts, seeks to have part of one executive order issued in January declared unconstitutional. The order targets gender-affirming care provided to people under the age of 19, such as puberty blockers, hormone therapy and surgical procedures, which it refers to as 'mutilation.' The lawsuit also asks the court to declare unlawful the Justice Department's targeting of providers of gender-affirming care. The section of the order that is being challenged directs the Justice Department to use laws such as the Food, Drug and Cosmetic Act, those against female genital mutilation, and child custody legislation to carry out the administration's aims. 'It is the policy of the United States that it will not fund, sponsor, promote, assist, or support the so-called 'transition' of a child from one sex to another,' Trump's order says, calling the treatments 'a stain on our Nation's history.' The states of Massachusetts, California, New York, Connecticut, Illinois, Delaware, Hawaii, Maine, Maryland, Michigan, Nevada, New Jersey, New Mexico, Rhode Island and Wisconsin, as well as the District of Columbia and Josh Shapiro in his capacity as Pennsylvania governor, filed suit. The lawsuit, filed against Trump, the Justice Department and Attorney General Pam Bondi, argues that the executive order conflicts with states' remit to regulate and police medicine and violates the 10th Amendment, which protects states' powers, and is in conflict with many state antidiscrimination laws. Nearly every major medical association endorses the availability of gender-affirming care for transgender young people, citing reductions in depression, substance abuse and suicide attempts. 'Empirical evidence has demonstrated that trans and nonbinary gender identities are normal variations of human identity and expression,' the American Medical Association has said. But the issue, and others related to transgender people, has animated conservatives. Trump has said he wants the 'official policy of the United States' to be that there are only two genders and has referred to being transgender as a 'falsehood.' The administration has moved to ban transgender service members from the military, relocate incarcerated transgender women into men's prisons and bar transgender people from using restrooms that align with their gender identity in federal buildings, among a slew of anti-trans measures, many of which have been challenged in court. After the January order, the lawsuit says, the Justice Department began 'intimidating providers into ceasing care through threats of civil and criminal prosecution.' 'These threats have no basis in law,' the complaint says. 'No federal law prohibits, much less criminalizes, the provision or receipt of gender-affirming care for transgender adolescents.' Puberty blockers temporarily inhibit sex hormones, such as estrogen and testosterone, and other hormone therapies introduce them to the body. Gender-affirming surgeries, such as breast reductions for transgender men, are rarely performed on minors. White House spokesperson Taylor Rogers said in an email that 'everyday Americans resoundingly support' the administration's actions. 'The President has the lawful authority to protect America's vulnerable children through executive action, and the Administration looks forward to ultimate victory on this issue,' she added. In June, the Supreme Court upheld a ban on gender-affirming care for minors in Tennessee.
Forbes
3 hours ago
- Forbes
Novel Access Model For Sickle Cell Disease Gene Therapy Could Be Template
The Centers for Medicare and Medicaid Services announced in July that 33 states, the District of Columbia and Puerto Rico will join a new voluntary program intended to improve patient access to and lower costs for gene therapies targeting sickle cell disease. This was a Biden administration initiative, which the Trump administration decided to continue to implement. It ties payment for two novel gene therapies to positive clinical outcomes. This could make such treatments that cost millions be more widely accessible for patients. And if successful, it may serve as a template for future cell and gene therapy agreements. Medicaid, the joint federal and state program that provides health coverage to low-income individuals, is the main insurer for SCD patients. The Biden administration announced last year that the manufacturers of Lyfgenia and Casgevy had entered into agreements with CMS to participate in the Cell and Gene Therapy Access Model, which allows CMS to negotiate outcomes-based agreements on behalf of state Medicaid programs for cell and gene therapies, beginning with sickle cell disease treatments. Essentially this means that CMS will reimburse based on whether certain agreed-upon clinical thresholds are reached in patients. According to CMS, the participating states in the newly established access initiative represent about 84% of Medicaid beneficiaries with SCD. The program could contribute towards a sizable expansion of access to potentially transformative care in the form of two extraordinarily expensive gene therapies. The launch prices for Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) were $2.2 million and $3.1 million, respectively. SCD is a group of congenital red blood cell disorders, named sickle cell for their crescent shape. The condition affects millions of people worldwide. In the United States, approximately 100,000 individuals are living with the disease, which predominantly impacts people of sub-Saharan African descent. The disease alters the structure of hemoglobin, the molecule in red blood cells that delivers oxygen to organs and tissue throughout the body. As a consequence, this causes severe pain, anemia, organ damage and infections. Individuals with the disease have a shorter life expectancy, by more than 20 years on average. The most common sickle cell disorder type is sickle cell anemia. Besides pain medications to relieve symptoms as well as antibiotics to treat infections, hydroxyurea—a bone marrow suppressive agent that decreases red blood cell production—can be used to reduce the frequency of painful episodes. It has been in use since the 1980s. The Food and Drug Administration has approved several new therapeutics in the past ten years, but none are as promising as Lyfgenia and Casgevy. These two novel therapies can decrease or potentially eliminate pain crises in patients. Gene therapies such as Lyfgenia and Casgevy are administered in an inpatient hospital setting but are considered covered outpatient drugs because they're directly reimbursed and subject to standard, federally mandated Medicaid rebates. Manufacturers of the two treatments must also provide states with supplemental rebates (post-hoc discounts off of the list price) reflecting model-negotiated terms. In turn, states are obligated to implement an agreed-upon access policy for patients. According to CMS, there is also optional federal support of up to $9.55 million per state available to help with implementation of the arrangements, outreach and data tracking. In the cell and gene therapy space, science has generally outpaced commercialization. Access to very costly treatments is a challenge. Whether in the public or commercial sector, payers must find novel ways of paying for cell and gene therapies while generating evidence with respect to their real-world effectiveness and safety. Questions insurers must find answers to include: What are the health outcomes for patients in real-world settings? Do treatments fulfill the promise of a one-time cure for certain serious illnesses or disorders? Are there particular safety concerns that appear in real-world settings? Are side effects manageable? Coordinating evidence gathering as well as contracts across state Medicaid agencies is likely to yield a more efficient process while improving access for a substantial majority of SCD sufferers nationwide. It's not just SCD gene therapies that confront a formidable set of barriers to access. All cell and gene therapy manufacturers face a challenging environment. The regulatory hurdles are enormous to begin with, but manufacturing challenges following approval are considerable, too. Furthermore, patient preparation, side effect and adverse event profiles can be intolerable. This can deter patients from signing up to initiate treatment. On top of all of this, payers concerned about the high per unit costs often impose coverage restrictions, as the Tufts Center for the Evaluation of Value and Risk in Health describes. Nonetheless, gene therapies in particular hold the promise of delivering groundbreaking improvements in health outcomes across multiple disease areas. Therefore, overcoming obstacles to optimal patient access is crucial. If successful, the SCD model being experimented with could serve as a blueprint for other cell and gene therapies that have faced considerable barriers with respect to patient access.
CBS News
8 hours ago
- CBS News
Pfizer CEO attending $25 million fundraiser at Trump's golf club after president demands drug price cuts, sources say
Pfizer CEO Albert Bourla is among those expected at a fundraiser President Trump is attending Friday at his golf club in Bedminster, New Jersey, sources told CBS News. The fundraiser for the pro-Trump super political action committee MAGA Inc. aims to raise about $25 million, one of the sources said. One day prior to the event, Mr. Trump sent letters to pharmaceutical companies, including Pfizer, demanding they lower U.S. drug prices to more evenly match what other countries pay. The White House's letters to 17 drug companies, including AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson and Sanofi, asked for commitments within 60 days to sell drugs for Medicaid patients and all new drugs at "most favored nation" rates. The president posted images of the letters to Truth Social. Mr. Trump signed an executive order in May telling federal officials to draw up "most favored nation" regulations unless pharmaceutical companies made progress toward cutting prices. This week's letters — which were addressed to Bourla and the other CEOs — accused the drugmakers of promising "more of the same" since then. The president said Friday he's "gone to war with the drug companies and, frankly, other countries" on the drug price issue. "I think we're going to be very successful fairly soon. We'll have drug prices coming down by 500, 600 800 even 1,200 percent," Mr. Trump said in an interview with Newsmax on Friday afternoon. The high cost of prescription drugs has vexed both parties for decades. Proposals to tie drug prices for U.S. patients to the typically much-lower rates charged in other developed countries have floated around for years, but the idea has faced some legal pushback. Meanwhile, drugmakers argue price caps could discourage innovation by making it harder to pay for research and development for new drugs. The industry also argues that Americans tend to have access to more groundbreaking drugs than residents of foreign countries with stricter price regulations — and says high drug prices are just one part of a broader trend of higher healthcare spending in the U.S. Bourla has engaged with Mr. Trump in the past. Pfizer was one of the drugmakers that was picked to rapidly develop COVID-19 vaccines in the first Trump administration's "Operation Warp Speed." And two weeks before Mr. Trump's second inauguration, Bourla and other Pfizer executives traveled to Mar-A-Lago for meetings, the Financial Times has previously reported. CBS News has reached out to Pfizer and the White House for comment.
